The idea for the one shot regimen—without a trial!—is already being pushed by very prominent politicians with a lot of power. I think the piece is pretty clear why this needs a trial. Of course I’m all for discussion especially since it needs resources and proper implementation.
-
-
Replying to @zeynep @angie_rasmussen and
Clarity abt RCT a moot pt. Again, doesn't justify a NYT op-ed vs. sci journal commentary for expert discussion you say you seek. Implies a "well the horse already left the barn" rationale. If powerful politicians pushing misinfo a concern, then addressing that shld've been focus.
1 reply 0 retweets 7 likes -
Replying to @RMCarpiano @angie_rasmussen and
There seems to be broad agreement—here at least—that a trial is warranted and a disagreement on: if this should be a public discussion and venue. On the first I don’t think we have a choice. We haven’t since the beginning. That’s been an ongoing contention of mine. +
1 reply 0 retweets 2 likes -
Replying to @zeynep @RMCarpiano and
On venue: Something like this needs attention and resources *and* public understanding—The fact I would argue exactly to prevent misinformation and misunderstanding. Doesn’t preclude other writing.
2 replies 0 retweets 2 likes -
Replying to @zeynep @RMCarpiano and
"While we know that the single dose can protect against disease" seems like a strong statement - these were post hoc analyses, right? Your piece doesn't help any reader understand why post hoc analyses are problematic.
0 replies 0 retweets 4 likes -
This Tweet is unavailable.
-
This Tweet is unavailable.
-
Replying to @K_G_Andersen @TAGHIVscience and
Weak yes - which is why we need the study. However, the data we DO have shows a 92% efficacy among people without a second dose. I don't see how this is so weak we should not seriously consider it. 2/983 vs 28/1059. Durability unknown - some ppl go out to 108 days.
1 reply 1 retweet 7 likes -
Replying to @michaelmina_lab @K_G_Andersen and
I have not seen the neutralization assays data after one injection...ADE is not something I would ignore...
0 replies 0 retweets 1 like -
This Tweet is unavailable.
We will hopefully not only do this kind of trial, I hope there will be long-term follow-up with an adaptive regime (if we are doing wish-lists here) so we can respond quickly if we do find significant waning—including after the double-dose regimen.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.